Figure 3 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

Changes in tumor and immune cell populations and phenotypes with anti–PD-1. A,CDK4 and MDM2 expression in tumor cells according to best response. PD, P03, before and after retifanlimab initiation (IO); SD, three before IO and six after IO. B, Signature scores in tumor cells according to best response. Same samples as in A. C, Integrated clustering of cancer cells from patients with paired samples and sufficient tumor fraction. D and E, Intracluster signature score changes with initiation of retifanlimab, plotted (D) along the x-axis or (E) as dot size. F, Volcano plot of differential expression of genes related to immune response in cluster 8 vs. all other clusters from P12.